MMS Maximus, Inc.

NYSE
$65.26

Maximus Tops Q4 Estimates, but FY27 Guidance Resets Earnings Lower as VA Incentives Disappear

Maximus closed fiscal 2026 with a strong fourth quarter. The forward picture it set up is weaker, and that is the central tension in the report. Adjusted EPS of $2.11 beat the $1.88 consensus by 12.2% and grew 30.2% year over year, well above the 12.0% full-year adjusted EPS growth rate. Revenue of $1.301 billion edged past the $1.29 billion estimate by 0.8% but fell 1.3% from a year ago. Full-year adjusted EPS of $8.24 cleared the top of guidance. Fiscal 2027 guidance of $7.50 to $8.00, however, puts the midpoint of $7.75 below what the company just earned and below the $8.25 to $8.55 range it was guiding to for fiscal 2026 as recently as the second quarter.

The quality of the fourth-quarter beat is better than a typical margin story, but it carries an expiration date. Q4 adjusted EBITDA margin reached 14.6%, up from 12.2% a year earlier. U.S. Federal Services margin jumped to 19.8% from 15.1%. That happened even though the quarter already reflected the customer-directed removal of VA Medical Disability Examination performance incentives. The lift came from strong clinical performance that management expects to moderate. GAAP diluted EPS rose to $1.83 from $1.32, so the improvement was not an adjustment artifact. Share count also helped: diluted shares fell roughly 7% year over year after about $192 million of fiscal 2026 buybacks.

The guidance shows how much of fiscal 2026 was non-recurring. The VA MDE incentives contributed about $75 million of revenue and an estimated $1.05 of adjusted EPS across the first three quarters. Fiscal 2027 assumes none of it. Excluding that benefit, the midpoint implies roughly 8% growth. Even so, consolidated adjusted EBITDA margin is guided down to about 12.8% from 14.2%, and federal segment margin to 14-15% from 18.1%. Revenue guidance of $5.45 to $5.65 billion looks like growth, but it includes about ten months of Agile Defense. Call commentary put implied organic growth at only about 1% at the midpoint on a pro forma basis. The core business is essentially flat, with Agile carrying the top line.

Cash flow was the quarter's other conflict. Fiscal 2026 free cash flow of just $69 million fell roughly $380 million short of the $450 to $500 million guide. Receivables swelled to $1.34 billion from $898 million a year earlier. Management attributes the shortfall to timing. It has collected more than $330 million from a major customer since year-end, and fiscal 2027 free cash flow guidance of $700 to $800 million assumes DSO returns to 60-70 days from 93. If those collections continue, the cash miss becomes a cash windfall. Investors should still watch whether that normalization arrives on schedule.

The forward catalysts are real but uneven:

  • **Bookings:** Q4 book-to-bill improved to 1.0x, the best of the year, after 0.2x in Q1. Awarded-but-unsigned contracts rose to $1.86 billion from $322 million in Q2, helped by an $800 million-plus, ten-year state Medicaid re-win at higher pricing. The recompete win rate was about 89%.
  • **U.S. Services:** The segment returned to organic growth in Q4 and is guided to mid-single-digit growth. Five states are now contracted for Medicaid community engagement work. A CMS option letting states suspend adverse actions for six months could slow that ramp.
  • **Pipeline:** The trailing book-to-bill remains 0.5x. The pipeline shrank to $44.8 billion from $56.8 billion in Q2, mainly because the VA MDE recompete carries a five-year term rather than the assumed ten, with no incentives.
  • **Agile Defense:** The deal brings about $450 million of calendar 2027 revenue and double-digit growth. It also lifts pro forma leverage to about 2.3x and interest expense to about $110 million.
  • **Outside the U.S.:** The segment posted a loss in fiscal 2026 and expects another in Q1.

Investor sentiment entered the report negative but improving, rising from -0.57 to -0.39. The stock has traded the same way. Shares sat at $65.26 before the release, up 12.7% from the post-August open of $57.90 and about 28% above the September 28 52-week low of $51.04. They had pulled back about 8% from the November 5 high of $70.98 and sat only 3.6% above the 200-day moving average of $62.98. The market had already priced in a good part of a recovery, so a guide below fiscal 2026 actuals leaves less room for error than the headline beat suggests.

The bottom line is that Maximus delivered a clean, high-quality fourth quarter and a credible cash-flow rebound story, but fiscal 2027 is a reset year. Earnings step down, margins compress, and organic growth is close to zero once Agile Defense is excluded. Bulls can point to improving bookings, state Medicaid momentum and a $700-800 million cash inflow funding buybacks. Bears have legitimate ammunition in the lost VA incentives, a shrinking pipeline and higher leverage. Execution on collections and the Agile integration will matter more than this quarter's beat.

← Back to MMS news

Read our preview of this report →